Joy Snider on Donanemab Approval Likely to Pose New Quandaries for Clinicians
COMMENT I was unable to tune in for the hearing, but from what I have heard from colleagues, we are overall happy to see the committee’s approval. I understand the committee’s reasoning in not requiring tau PET. I also agree with Dr. Knopman’s point in his Alzfor